Endpoint Determination Study Protocol

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

556 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-21

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate the most applicable endpoints for evaluation of the Biomerica InFoods® IBS product.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diet Reintroduction Study in Irritable Bowel Syndrome

NCT03052439

Irritable Bowel Syndrome

COMPLETED NA

IBS Skin Patch Test Food Allergy Study

NCT06288672

Irritable Bowel Syndrome

RECRUITING NA

The Effect of Dietary Intervention on Symptoms, Epigenetics, and Gut Microbiota in IBS

NCT03306381

IBS - Irritable Bowel Syndrome

COMPLETED NA

A Clinical Trial Evaluating Diets for IBS

NCT05831306

Irritable Bowel Syndrome

UNKNOWN NA

Irritable Bowel Syndrome and Food Sensitivity

NCT02186743

Irritable Bowel Syndrome

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this Endpoint Determination Study is to address key elements regarding a proposed larger clinical study design:

1. Comparing different potential primary outcome measures
2. Demonstrating that an exclusionary diet as determined by elevated IgG levels using the Biomerica InFoods® IBS Test is associated with alleviation of IBS symptoms
3. Demonstrating the ability to mask the sham diet
4. Demonstrating the safety of the exclusionary diet

Subjects' diets will be based on the results of the Biomerica, InFoods® IBS Test.

Immunoglobulin G (IgG) levels above a certain threshold are considered a positive response against a specific food or foods. It is expected that severity of symptoms of IBS will decrease when foods that generate a positive immune response in the Biomerica InFoods® IBS test are eliminated from the diet of the IBS patient.

The Endpoint Determination Study format will be a double-blinded randomized controlled clinical study enrolling subjects at two trial sites within the United States and designed to evaluate the use of IgG antibody guided dietary restrictions, based on the Biomerica InFoods® IBS Test, in the management of patients diagnosed with Irritable Bowel Syndrome (IBS).

The 2 sites will enroll approximately equal numbers of subjects. The target for each site is a minimum of 30 subjects in each classification: IBS with diarrhea \[IBS-D\], IBS with constipation \[IBS-C\] and IBS mixed \[IBS-M\] for a minimum of 90 patients per site, 180 total subjects for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel Design

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 - True Food Elimination Diet

Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.

Group Type EXPERIMENTAL

Food Elimination Diet

Intervention Type OTHER

Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms

Group 2 - Sham Food Elimination Diet

Group 2 (control group): Subjects will be given a "Sham" elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.

Group Type SHAM_COMPARATOR

Food Elimination Diet

Intervention Type OTHER

Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Food Elimination Diet

Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 21 years old or older.
* Able to read and understand English.
* Willing and able to sign the informed consent.
* Have access to a computer and/or cell phone access for Electronic Data Capture (EDC)
* Meets Rome IV Diagnostic Criteria for IBS
* Willing to follow a food elimination die
* Well controlled diabetic patients; A1C \<7.5 and stable medication (\>3 months, NOT Metformin
* Score between ≥ 3 and \<7.5 on the Abdominal Pain Intensity Assessment (IBS\_API) based on a weekly average of worst daily (in past 24 hours) abdominal pain on a 0 to 10 point scale.
* Patients who are on stable (\> 3 months) doses of medications or treatments for their IBS (e.g., probiotics, fiber, Viberzi, Linzess, Amitiza, Alosetron, Plecanatide, anticholinergics, antidepressants, Zofran bile acid sequestrants, or anti-diarrheals) will be allowed to continue their medications as long as no change in treatment is planned for the duration of the study and no dose adjustment is made during the duration of the study.
* A positive IgG antibody response for at least one food in the Biomerica InFoods® IBS panel

Exclusion Criteria

* Unable to provide consent.
* Cannot use EDC system due to no cell phone and no computer access
* Does not qualify for a diagnosis of IBS by IV Diagnostic Criteria
* Diagnosed IBS, but an IBS-API score of \<3.0 and \>7.5
* Pregnant or breastfeeding
* Patients with diabetes currently on Metformin
* Patients who have used Rifaximin in the past 3 months
* Patients engaged in another type of diet therapy, i.e. FODMAP
* Patients which physicians are anticipating starting a new medication, change in dosage, diet or other treatment for IBS during the study
* Chronic pain from other conditions besides IBS
* Current or previous use of narcotic medications within past 3 months
* History of prior GI surgery except for cholecystectomy or appendectomy.
* History with any of the following:

Gastroparesis, Uncontrolled GERD, Anorexia/bulimia Celiac disease Crohn's disease, Ulcerative Colitis, Abdominal/gastro cancer(s), Malabsorption syndrome(s).

* History of any other relevant inter-current medical conditions that could interfere with their participation in the study or the objectives of the study
* History of psychosis, schizophrenia, mania, or major psychiatric illness needing hospitalization within the past 6 months

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No